Full TitleA Phase 2, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients with Relapsed or Refractory Hodgkin Lymphoma
The purpose of this study is to assess the safety and effectiveness of the investigational drug camidanlumab tesirine in patients with Hodgkin lymphoma that came back or continued to grow despite prior treatment. Camidanlumab tesirine is an antibody drug conjugate: a type of drug that combines an antibody with a chemotherapy drug. The antibody part targets the protein CD25, which is present in high amounts on Hodgkin lymphoma cells. The chemotherapy part is a drug, SG3199, that may kill the cancer cells the antibody part sticks to. Camidanlumab tesirine is given intravenously (by vein).
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have classical Hodgkin lymphoma that came back or continued to grow after at least three prior regimens of therapy (or at least two prior regimens for patients not eligible for stem cell transplantation), including brentuximab vedotin and immunotherapy (nivolumab or pembrolizumab).
- At least 2 weeks must pass since the completion of prior treatments (60 days since a stem cell transplant) and receipt of camidanlumab tesirine.
- Patients must be able to walk and do routine activities for more than half of their normal waking hours.
- This study is for patients age 18 and older.
For more information about this study and to inquire about eligibility, please contact Dr. Alison Moskowitz at 646-608-3726.